FDA slaps partial hold on MacroGenics for bispecific cancer trials as liver tox spurs safety fears
Leery about signs of liver toxicity among patients taking a B7-H3 × CD3 bispecific under development at MacroGenics $MGNX, the FDA has slapped a partial hold on the early-stage program.
The partial hold — which affects their monotherapy trial as well a combination effort with their own PD-1 checkpoint MGA012, partnered with Incyte — will stop researchers from recruiting new patients, but people who have already signed up can continue treatment.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.